Phase 3 trial of IPI-145: Infinity... - CLL Support

CLL Support

23,088 members39,651 posts

Phase 3 trial of IPI-145

Cllcanada profile image
CllcanadaTop Poster CURE Hero
0 Replies

Infinity Pharmaceuticals, Inc. announced that, in the fourth quarter of 2013, it expects to initiate a Phase 3 trial of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

This randomized study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg twice daily (BID) compared to ofatumumab in approximately 300 relapsed or refractory patients.

online.wsj.com/article/PR-C...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

CLL-ipi; is it accurate?????

https://www.mdcalc.com/international-prognostic-index-chronic-lymphocytic-leukemia-cll-ipi#why-use...

OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for...

AbbVie Pharm--positive phase 3 for CLL!

Hey, all, see this article about AbbVie pharma! AbbVie Sees Continued Positive Results for...

Determining if you'll never need treatment. It is feasible and safe to stop specialized follow-up of asymptomatic lower risk CLL?

Regular readers will have often heard that around 30% of those diagnosed with CLL never need...

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce...